MELISI, DAVIDE
 Distribuzione geografica
Continente #
NA - Nord America 171
EU - Europa 71
AS - Asia 51
AF - Africa 3
Totale 296
Nazione #
US - Stati Uniti d'America 167
UA - Ucraina 28
SG - Singapore 17
HK - Hong Kong 14
CN - Cina 11
IE - Irlanda 10
PK - Pakistan 9
IT - Italia 8
FI - Finlandia 6
NL - Olanda 6
CA - Canada 4
DE - Germania 4
GB - Regno Unito 4
CI - Costa d'Avorio 3
SE - Svezia 3
FR - Francia 2
Totale 296
Città #
Jacksonville 30
Chandler 19
Hong Kong 14
Singapore 14
Woodbridge 14
Ann Arbor 10
Santa Clara 10
Houston 9
Islamabad 9
Ashburn 7
Millbury 7
Boston 6
Nanjing 6
Amsterdam 4
Boardman 3
Ottawa 3
Wilmington 3
Aversa 2
Beijing 2
Norwalk 2
Princeton 2
Des Moines 1
Hebei 1
Jiaxing 1
Nanchang 1
Palma Campania 1
Toronto 1
Walnut 1
Totale 183
Nome #
Angiogenesis: A target for cancer therapy. 50
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 49
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 47
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 46
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. 42
Key cancer cell signal transduction pathways as therapeutic targets. 38
Peroxiredoxin-2 plays a pivotal role as multimodal cytoprotector in the early phase of pulmonary hypertension 30
Totale 302
Categoria #
all - tutte 1.356
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.356


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 2 3 4
2020/202151 0 4 8 6 6 6 7 0 6 0 8 0
2021/202242 0 0 0 2 0 1 0 1 11 0 13 14
2022/202339 2 5 0 0 11 2 0 3 8 4 4 0
2023/202439 1 2 4 10 3 0 9 3 0 0 7 0
2024/202545 6 5 0 0 11 7 16 0 0 0 0 0
Totale 302